image: GeniPhys was issued an additional new patent on its Collymer platform technology, which includes a first-in-kind flowable collagen liquid used to fill tissue defects and voids. Collymer SAS transitions into fibrillar collagen scaffolding that replicates natural collagen for full tissue-appropriate integration and remodeling.
Credit: (Photo by William Cabral)
INDIANAPOLIS – GeniPhys, an Indianapolis-based medtech innovator of regenerative collagen polymeric biomaterials, announced today that the U.S. Patent and Trademark Office has issued a patent that expands protection of its platform technology Collymer and the processing methods that support applications for material diversity.
Collymer can be designed and fabricated into materials with a variety of flexible shapes, architectures and mechanical properties to address unmet clinical needs in advanced wound care, soft tissue reconstruction in breast-conserving surgery/lumpectomy, aesthetics, orthopedics, and therapeutic cell and drug delivery.
“Strengthening and protecting our growing intellectual property portfolio is a top priority for GeniPhys,” said Andy Eibling, president and CEO of GeniPhys. “Collymer represents a paradigm shift in how we think about regenerative medicine and healing. This new issuance builds on prior applications that protect our novel concept and manufacturing methods and opens additional applications of Collymer to more procedures that leverage its distinctive noninflammatory response and regenerative remodeling mechanism of action.”
Collymer was developed by GeniPhys founder and Chief Technology Officer Sherry Harbin, professor of biomedical engineering and courtesy professor of basic medical sciences at Purdue University. The technology is licensed to GeniPhys by the Purdue Innovates Office of Technology Commercialization and is the cornerstone of the company’s broad intellectual property portfolio, which now includes nearly 20 approved or pending patents in the U.S. and other countries.
GeniPhys is on track for FDA 510(k) submission and clearance by Q2 2025, enabling entry into the advanced wound care market with its first product, Collymer Self-Assembling Scaffold (SAS). This first-in-kind product is applied as a flowable collagen liquid to tissue defects and voids. During application, Collymer SAS fills the wound void and conforms to its geometry prior to rapidly transitioning into fibrillar collagen scaffold. Its structural and biochemical signals replicate those of natural collagen for full tissue-appropriate integration and remodeling without causing inflammation or scar tissue formation – providing increased opportunities for improved patient outcomes, shorter healing times and the potential for more cost-effective treatments.
The GeniPhys vision is to become a global manufacturer and supplier of its Collymer biopolymer as well as next-generation implantable collagen polymeric materials for improved tissue restoration outcomes. For more information about GeniPhys and its Collymer platform technology, visit GeniPhys.
Media Contact: Sue Goin, sue.goin@sapphire-com